Reply of the Authors: Levonorgestrel–releasing intra–uterine systems (LNG-IUS) and breast cancer

Abstract

We thank Neven et al. for their letter. We agree that our published data does not provide robust evidence to draw firm conclusions. The abstract clearly states: “Overall, we did not find an increased risk of breast cancer recurrence associated with the use of the LNG IUS. However, in a subgroup analysis of women who developed breast cancer while using an LNG IUS and who continued to use the LNG IUS, we found a higher risk of recurrence of borderline statistical significance. Additional research is needed to confirm or refute these findings.”